Articles On Cyclopharm (ASX:CYC)

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

  The US market closed slightly higher on Friday but overall finished the week lower as concerns resurfaced that the Federal Reserve may raise rates more than previously expected. Recent economic data, including lower-than-expected initial...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABY)) - Adore Beauty ((ASG)) - Autosports Group ((CHL)) - Camplify Holdings ((CWP)) - Cedar Woods Properties ((CGS)) - Cogstate ((CTD)) - Corporate Travel Management ((C...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in...

The US FDA has completed inspection of Cyclopharm’s facility Next Science says XPERIENCE reduces knee inflammation Anteris takes one step further toward receiving FDA approval   Cyclopharm confident of FDA timeline after inspection Cyclop...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

ASX chopped about sideways, losing any slight semblance of  fizz at close: -0.063% IT, Discretionary and Industrials led sectors, while Materials lagged The day’s clear winner was Mantle Minerals, up 50% at day’s end on further exploration...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Joe Biden might have snubbed our leaders in favour of dealing with a wee $US31 trillion debt issue at home, but lung imaging house 4D Medical (ASX:4DX) still has 420 billion reasons to call POTUS a buddy. That’s because Congress has allocat...

Many Aussie biotechs have endured a long wait to secure US Food and Drug Administration (FDA) approval for their drugs and devices, but Cyclopharm’s three-decade quest for the agency’s imprimatur surely sets the record. On September 29, 202...

Cyclopharm (ASX:CYC) has announced that it has been notified that the US FDA will inspect the company's Kinsgrove facility between late July and early August.

The ASX will open flattish on Tuesday Crude prices rise another 2pc overnight The market awaits the Federal Budget later tonight   The ASX is poised to open modestly higher on Tuesday after a flat session on Wall Street overnight. US trad...

By Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS. For the purpose of bro...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

ShareCafeOPEC oil cut gives Energy sector a big boost                    The Dow Jones Industrial Average added more than 300 points overnight, as Wall Street shows resilience despite an oil output cut from OPEC+ that threatens to sto...

ShareCafeDeutsche Bank the latest international bank to tumble                    Stocks rose Friday after a volatile trading session. Although Friday began with fears that the banking crisis was spilling over to Deutsche Bank, the ma...

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

All Ordinaries Index (ASX: XAO) shares closed up 0.7% on Friday. That helped the All Ords post a gain of 1.2% for the first week of trading in 2023. Investors will certainly welcome this start to the new year after All Ordinaries shares dr...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

ASX 200 ends flat again Small caps gain a little bit ELO, DRO and EOS rise like legends   There are some mixed feelings around the neighbourhood heading into this latest gut churning measure of US inflation tonight. US futures are slightl...

ASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge    We’re pretty flat on Wednesday. I am, the benchmark is and so is Australia as a nation and a continent. Luckily Gregor Stronach, my trusty fiend on...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

ShareCafeKey week for US economic data as indexes produce strong weekly gains                    US equities were higher in Friday trading, finishing just off best levels. Each of the major averages were up more than 2.5 per cent for...

ShareCafeBiden Administration moves to ban chip sales into China                    The Dow Jones Industrial Average and the S&P 500 ended the first day of September on a high note as traders looked forward to the jobs report tomo...

Radiopharmaceutical company Cyclopharm Limited (ASX:CYC) has announced results for the six-months to the end of June. The company said the results include record consolidated group revenue of...

The ASX 200 is set to open higher on Wednesday Wall Street was mixed overnight Oil is at the lowest level in six months Local shares are set to open higher today. At 8am AEST, the ASX 200 August futures contract is pointing up by 0.10%. O...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Botanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx platform Cyclopharm’s Technegas is used ahead of competitor products in Covid-19 diagnosis Clinical dermatology company, Botanix Pharma (A...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Highlights The ASX 200 index is likely to open lower on Tuesday tracking lower global equities. U.S equity markets ended sharply lower on Monday as investors sold tech shares in the wake of surging U.S. treasury yields. Bond yields ro...

Highlights Companies like Beacon Minerals, Cyclopharm and Sigma Healthcare will be turning ex-dividend on Monday (4 April 2022). The ex-dividend date is usually one day (business day) before the record date for stocks. Investors get t...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader index which is down by 0.37%. Visioneering Technologies (ASX:VTI) has enrolled the first patient in its landmark international clinical trial...

The ASX is suffering today in what could be a reaction to a disastrous session in the United States. But, interestingly, one All Ordinaries Index (ASX: XAO) share has been thriving. While most of Australia slept, the Nasdaq Composite Index...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...